Physician profile
Kendra E Stark
NPI 1376325126
$1,509.30
in general payments reported to CMS, 2019-2025
18 companies · $573 in 2025
The $573 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.31 · 2024: $920 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $348.57 | 2024-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $212.28 | 2024-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $171.06 | 2024-2025 | |
| Pfizer INC. | $119.12 | 2025 | |
| Heartflow, INC. | $98.18 | 2024-2025 | |
| Abiomed | $97.90 | 2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $92.98 | 2024-2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $68.91 | 2023-2025 | Watchman Flx, Watchman Access System |
| Alnylam Pharmaceuticals INC. | $65.85 | 2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.50 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $49.62 | 2024-2025 | Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.20 | 2025 | Lifevest |
| Scpharmaceuticals INC. | $19.24 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.34 | 2024 | Xarelto |
| Esperion Therapeutics, INC. | $15.69 | 2024 | Nexletol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15.46 | 2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $15.43 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.97 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.